secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-05-11T21:10:04+00:00
Accession:  0001193125-26-217100
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere closes $525M 0.50% convertible note offering; uses proceeds to repurchase $221.4M of 2029 notes
--------------------------------------------------------------------------------

- Closed offering of $525M aggregate principal of 0.50% Convertible Senior Notes due 2032; net proceeds est. $508.5M.
- Initial conversion price ~$64.90/share (15.4078 shares per $1,000 principal); notes mature May 15, 2032.
- To repurchase $221.4M of outstanding 2.25% 2029 notes for approx. $350.9M, including accrued interest.
- Remaining net proceeds for general corporate purposes, including commercialization and R&D.
- Underwriters' over-allotment option fully exercised; offering upsized from $400M to $475M then to $525M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/0001193125-26-217100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/d38424d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-217100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer